L
Luis M. Ruilope
Researcher at European University of Madrid
Publications - 891
Citations - 109166
Luis M. Ruilope is an academic researcher from European University of Madrid. The author has contributed to research in topics: Blood pressure & Renal function. The author has an hindex of 94, co-authored 841 publications receiving 97778 citations. Previous affiliations of Luis M. Ruilope include Lund University & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Do we need to target 'prediabetic' hypertensive patients?
TL;DR: The need of targeting 'prediabetic' hypertensive patients in order to develop strategies for cardiovascular protection intended to diminish the consequences of precipitating the development of diabetes and its cardiovascular and renal deleterious effects is analyzed.
Journal ArticleDOI
Guías de práctica clínica sobre prevención de la enfermedad cardiovascular. Versión corregida 22/07/2009
Ian D. Graham,Dan Atar,Knut Borch-Johnsen,Gudrun Boysen,Gunilla Burell,Renata Cifkova,Jean Dallongeville,Guy De Backer,Shah Ebrahim,Bjørn Gjelsvik,Christoph Herrmann-Lingen,Arno W. Hoes,Steve E. Humphries,Mike Knapton,Joep Perk,Silvia G. Priori,Kalevi Pyörälä,Željko Reiner,Luis M. Ruilope,Susana Sans-Menendez,Wilma J.M. Scholte op Reimer,Peter L. Weissberg,David A. Wood,John Yarnell,José Luis Zamorano +24 more
TL;DR: Cuarto Grupo de Trabajo Conjunto de la Sociedad Europea de Cardiología y otras Sociedades sobre Prevención de the Enfermedad Cardiovascular en the Práctica Clínica (constituido por representantes de nueve sociedades y expertos invitados)
Journal ArticleDOI
Prospective comparison of therapeutical attitudes in hypertensive type 2 diabetic patients uncontrolled on monotherapy. A randomized trial: the EDICTA study
Luis M. Ruilope,A. de la Sierra,Erika Moreno,R. Fernández,Juan Luis Garrido,M. de la Figuera,A G de la Cámara,A. Coca,M. Luque-Otero +8 more
TL;DR: In type 2 hypertensive patients with uncontrolled BP despite anti-hypertensive monotherapy, the change to combination therapy was more effective in attaining DBP control than any monotherapy schedule.
Journal ArticleDOI
Predictors for the development of microalbuminuria and interaction with renal function
Christos Chatzikyrkou,Jan Menne,Joseph L. Izzo,Giancarlo Viberti,Ton J. Rabelink,Luis M. Ruilope,Christian Rump,Peter R. Mertens,Hermann Haller +8 more
TL;DR: Predictors of new onset microalbuminuria are the classical cardiovascular risk factors, followed by age, weight, glycosylated hemoglobin type A1C, blood glucose, total cholesterol, SBP number of antihypertensive drugs and heart rate.
Journal ArticleDOI
Dual-Acting Angiotensin Receptor–Neprilysin Inhibition
Julian Segura,Luis M. Ruilope +1 more
TL;DR: The dual inhibition of the angiotensin II receptor and neprilysin could provide clinical benefits in a range of cardiovascular diseases, including hypertension and heart failure.